The US Food and Drug Administration (FDA) late Friday issued revised versions of two final guidance documents explaining the use of bulk drug substances in compounding and clarifying that the agency ...

When we think of compounding, which is the process of combining, mixing, or altering ingredients to create a medication specific to the needs of an individual patient, we think of the Cars’ 1978 ...

The Food and Drug Administration (“FDA”) has released draft interim guidance documents that impact the use of bulk drug substances in compounding under Sections 503A and 503B of the Federal Food, Drug ...

The FDA’s recommendation against adding seven peptides to the 503A Bulk List weighs on Hims & Hers Health Inc‘s HIMS peptide ...

According to internal financial records, the pharmacy dispensed nearly 3 million individual prescriptions to patients ...

The FDA puts forward a move to exclude GLP-1 drugs from the bulk compounding list. Image credit: VICTOR TORRES/Stocksy According to the FDA's announcement, the organization is asking for submitted ...

In April, FDA detailed its priorities for drug compounding in 2019, which include issuing a new proposed rule to update the list of bulk drug substances that can be used in compounding under Section ...